A few cancer medicines can make the smallest blood vessels leaky, so fluid and protein seep out of the blood into the tissues. The signs are weight gain, swelling, breathlessness and low blood pressure. Teams watch weight, blood pressure and, for some of these medicines, a blood protein called albumin. If signs appear they pause the medicine and treat by that medicine's own rules.
Capillary leak syndrome (CLS) is loss of protein-rich fluid from the circulation: hypoalbuminaemia, oedema and weight gain, hypotension, and in severe cases pulmonary oedema, shock and acute kidney injury. Among anticancer drugs with records here, tagraxofusp and aldesleukin carry boxed warnings for it, dinutuximab and dinutuximab beta list it as a warning, and gemcitabine's label tells prescribers to stop the drug for good.
The tagraxofusp label has the most detailed rules. Albumin must be at least 3.2 g/dL before the first dose; cycle 1 is given in hospital; vital signs, albumin, transaminases and creatinine are checked before every dose. During dosing, an albumin below 3.5 g/dL or a fall of 0.5 g/dL or more from the start of the cycle, or a weight gain of 1.5 kg or more over the previous day's pre-dose weight, means the dose is held and 25 g of intravenous albumin is given every 12 hours or more often; oedema, fluid overload or hypotension add methylprednisolone 1 mg/kg a day and active fluid and blood pressure management. The label reports CLS in 53% of 122 patients by a broad definition, a median onset of 4 days, and four deaths.
Dinutuximab (children with high-risk neuroblastoma) needs 10 mL/kg of 0.9% saline over an hour before each infusion, close blood pressure monitoring, interruption for moderate to severe CLS with restart at half rate, and permanent discontinuation if life-threatening CLS recurs. The EU label for dinutuximab beta says the leak usually develops within hours of starting treatment, with low blood pressure and a fast pulse reported after 2 to 12 hours, and stops the drug for good for recurrent or grade 4 CLS. Aldesleukin is given only in a hospital with an intensive care facility and is withheld when organ perfusion fails.
The sources pull in different directions on fluids: the dinutuximab label requires pre-hydration and the tagraxofusp label uses intravenous fluids for hypotension, while the review of anticancer drug-induced CLS says saline should be limited because it worsens oedema. None of the sources read cites a randomised trial of albumin, steroids or any fluid strategy for drug-induced CLS. The reader's own team's protocol comes first.
Why: The label makes both a condition of starting, and warns that capillary leak on tagraxofusp can be life-threatening or fatal.
“Before initiating therapy with ELZONRIS, ensure that the patient has adequate cardiac function and serum albumin is greater than or equal to 3.2 g/dL.”
Stemline Therapeutics, a Menarini Group company (DailyMed, US National Library of Medicine) 2024
Why: In the label's trial data all but 5 of the 65 patients with capillary leak had it in the first cycle, at a median of 4 days.
“Administer Cycle 1 of ELZONRIS in the inpatient setting with patient observation through at least 24 hours after the last infusion.”
Stemline Therapeutics, a Menarini Group company (DailyMed, US National Library of Medicine) 2024
Why: The label's rules for holding a dose and treating capillary leak depend on these results, so they are seen before the dose is made up.
“Monitor vital signs and check albumin, transaminases, and creatinine prior to preparing each dose of ELZONRIS.”
Stemline Therapeutics, a Menarini Group company (DailyMed, US National Library of Medicine) 2024
Why: On tagraxofusp the label acts on a pre-dose weight 1.5 kg or more above the previous day's pre-dose weight, and it lists weight gain among the signs of leak.
“Advise patients to weigh themselves daily”
Stemline Therapeutics, a Menarini Group company (DailyMed, US National Library of Medicine) 2024
Why: The label treats a falling albumin as a sign of capillary leak and interrupts dosing until it has resolved.
“Administer 25g intravenous albumin (q12h or more frequently as practical) until serum albumin is ≥ 3.5 g/dL AND not more than 0.5 g/dL lower than the value measured prior to dosing initiation of the current cycle.”
Stemline Therapeutics, a Menarini Group company (DailyMed, US National Library of Medicine) 2024
Why: The label matches the fluid treatment to the blood pressure and continues until the weight gain has resolved.
“manage fluid status as indicated clinically (e.g., generally with intravenous fluids and vasopressors if hypotensive and with diuretics if normotensive or hypertensive)”
Stemline Therapeutics, a Menarini Group company (DailyMed, US National Library of Medicine) 2024
Why: This is the label's rule once the leak is causing these signs. The label does not give a reason for the steroid.
“Administer 1 mg/kg of methylprednisolone (or an equivalent) per day, until resolution of CLS sign/symptom or as indicated clinically.”
Stemline Therapeutics, a Menarini Group company (DailyMed, US National Library of Medicine) 2024
Why: The label allows the next cycle only once every sign has resolved and the blood pressure is stable.
“ELZONRIS administration should be held for the remainder of the cycle if CLS signs/symptoms have not resolved or the patient required measures to treat hemodynamic instability”
Stemline Therapeutics, a Menarini Group company (DailyMed, US National Library of Medicine) 2024
Why: The label requires this hydration before every infusion, under its warnings on capillary leak and low blood pressure.
“Administer 0.9% Sodium Chloride Injection, USP 10 mL/kg as an intravenous infusion over 1 hour just prior to initiating each Unituxin infusion.”
United Therapeutics (DailyMed, US National Library of Medicine) 2026
Why: Severe capillary leak happened in 31 patients (23%) given dinutuximab in the registration trial, and the label manages it by interrupting, slowing or stopping the infusion.
“Immediately interrupt or discontinue Unituxin and institute supportive management in patients with symptomatic or severe capillary leak syndrome”
United Therapeutics (DailyMed, US National Library of Medicine) 2026
Why: The EU label says the leak usually develops within hours of starting treatment, and that low blood pressure and a fast pulse are reported after 2 to 12 hours.
“Careful monitoring of circulatory and respiratory function is required.”
European Medicines Agency (marketing authorisation holder Recordati Netherlands B.V.) 2026
Why: The label says capillary leak may begin immediately after aldesleukin is started and can damage the heart, lungs, kidneys and liver.
“Monitor for signs and symptoms of CLS including assessments of vital signs, weight, fluid intake, albumin levels and urine output.”
Iovance Biotherapeutics (DailyMed, US National Library of Medicine) 2024
Why: The label lists these as the signs that organs are no longer being supplied with enough blood.
“Withhold or discontinue Proleukin for failure to maintain organ perfusion as demonstrated by altered mental status, reduced urine output, oxygen saturation <90%, a fall in the systolic blood pressure below 90 mm Hg, or onset of cardiac arrhythmias.”
Iovance Biotherapeutics (DailyMed, US National Library of Medicine) 2024
Why: The label reports severe consequences and gives no rule for restarting.
“Permanently discontinue Gemcitabine for Injection if CLS develops during therapy.”
Sagent Pharmaceuticals (DailyMed, US National Library of Medicine) 2026
Why: The consensus paper lists these checks among its precautions for tagraxofusp. It gives no reason, and they are in its discussion, not one of its listed recommendations.
“in addition to other standard practices evaluating for infection/sepsis, other cardiac/pulmonary events during the suspected time of CLS”
HemaSphere (Pagano et al.; no funding statement printed; several panel members declare roles with Stemline or Menarini, which market tagraxofusp) 2023 · Consensus position paper, discussion text; not graded
Why: The review says saline may worsen the swelling of the surrounding tissues and may damage limb muscles and nerves. The labels above use fluids differently; see the variants.
“As in idiopathic CLS, administration of saline infusions to restore intravascular volume should be limited as it may worsen the edema of the surrounding tissues and potentially cause damage to limb muscles and nerves.”
Why: The label says capillary leak may be life-threatening or fatal if it is not properly managed. It does not say how quickly to call.
“to contact their health care professional for signs and symptoms associated with CLS including new or worsening edema, weight gain, shortness of breath, and/or hypotension after infusion.”
Stemline Therapeutics, a Menarini Group company (DailyMed, US National Library of Medicine) 2024
Why: The aldesleukin label asks for an immediate report. The dinutuximab label likewise tells patients and caregivers to report any signs or symptoms immediately.
“Advise patients about the risk of capillary leak syndrome and to inform their healthcare provider immediately if they develop new or worsening symptoms of hypotension, dyspnea, or edema”
Iovance Biotherapeutics (DailyMed, US National Library of Medicine) 2024
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
For tagraxofusp, the label's own scheme is the most specific rule among the sources read, and the consensus paper on blastic plasmacytoid dendritic cell neoplasm lists the same kinds of precaution without thresholds or doses. The label's scheme: albumin of at least 3.2 g/dL before the first dose, cycle 1 in hospital, albumin, weight and vital signs before every dose, the dose held and 25 g of intravenous albumin given every 12 hours or more often when albumin falls below 3.5 g/dL (or by 0.5 g/dL or more from the start of the cycle) or weight rises 1.5 kg or more in a day, methylprednisolone 1 mg/kg a day for oedema, fluid overload or hypotension, and no further doses that cycle after haemodynamic instability. For the other drugs the labels give stopping rules and little else: dinutuximab with pre-hydration, interruption and restart at half rate; dinutuximab beta stopped for recurrent or grade 4 leak; aldesleukin withheld for failed organ perfusion; gemcitabine stopped for good. On fluids the sources differ and both views are shown: pre-hydration and fluids for hypotension in the dinutuximab and tagraxofusp labels, against the reviewers' advice to limit saline because it worsens oedema. None of the sources read cites a comparative trial.
Stemline Therapeutics, a Menarini Group company (DailyMed, US National Library of Medicine) 2024 · HemaSphere (Pagano et al.; no funding statement printed; several panel members declare roles with Stemline or Menarini, which market tagraxofusp) 2023 · United Therapeutics (DailyMed, US National Library of Medicine) 2026 · European Medicines Agency (marketing authorisation holder Recordati Netherlands B.V.) 2026 · Iovance Biotherapeutics (DailyMed, US National Library of Medicine) 2024 · Sagent Pharmaceuticals (DailyMed, US National Library of Medicine) 2026 · Kidney International Reports (Izzedine et al.) 2022
Where it differs: The dinutuximab label requires 10 mL/kg of saline before every infusion and the tagraxofusp label uses intravenous fluids and vasopressors for hypotension. The review of anticancer drug-induced capillary leak says saline to restore volume should be limited, notes that albumin's effect is blunted because it leaks too, and that starch solutions have been linked to more deaths and kidney injury in the critically ill.
Evidence: The sources read cite no comparative data. The review states: there is a lack of evidence to guide the choice of fluid therapy.
United Therapeutics (DailyMed, US National Library of Medicine) 2026 · Stemline Therapeutics, a Menarini Group company (DailyMed, US National Library of Medicine) 2024 · Kidney International Reports (Izzedine et al.) 2022
Where it differs: The US label interrupts dinutuximab for moderate to severe leak and resumes at 50% of the previous rate; for life-threatening leak it stops for the cycle, gives later cycles at 50% rate, and stops for good on first recurrence. The EU label for dinutuximab beta interrupts, resumes at 50% rate once the reaction resolves or improves to grade 1 to 2, and stops for good for recurrent or grade 4 leak (needing a ventilator).
Evidence: Label rules. Severe (grade 3 to 5) leak occurred in 31 of the children (23%) given dinutuximab in the registration trial; the EU label says that overall 5.2% of capillary leak was severe (grade 3 to 4) and that its frequency fell over the treatment courses, and it lists capillary leak at 35% across investigator-sponsored studies. The two products, their schedules and the drugs given with them differ, so the figures are not a comparison.
United Therapeutics (DailyMed, US National Library of Medicine) 2026 · European Medicines Agency (marketing authorisation holder Recordati Netherlands B.V.) 2026
Where it differs: The review suggests amiloride as the diuretic because it lowers blood pressure less, and lists steroids, aminophylline, theophylline or terbutaline, thalidomide, antihistamines, plasmapheresis and intravenous immunoglobulin as agents tried in secondary capillary leak. The tagraxofusp label names diuretics only as a class and steroids as methylprednisolone.
Evidence: The review says these agents have been tried sporadically with varying effect, and cites case reports. It states that intravenous immunoglobulin, which may help in the idiopathic form, has no documented efficacy in forms caused by anticancer drugs.
Kidney International Reports (Izzedine et al.) 2022 · Stemline Therapeutics, a Menarini Group company (DailyMed, US National Library of Medicine) 2024
Where it differs: A 2025 paper by eleven authors, one of them affiliated with the Menarini Group, funded by the Menarini Group (which markets tagraxofusp), discusses patient selection, monitoring and early intervention in practice. Only its abstract was read.
Evidence: The abstract quotes capillary leak in 21% of patients at 12 micrograms/kg a day in the registration trial, mostly grade 2, with two deaths, and says that with strict monitoring it is typically mild and mostly in cycle 1. No recommendation here rests on it.
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Tagraxofusp: monitor albumin before each dose and assess for weight gain, oedema, pulmonary oedema and hypotension “During treatment with ELZONRIS, monitor serum albumin levels prior to the initiation of each dose of ELZONRIS and as indicated clinically thereafter, and assess patients for other signs or symptoms of CLS, including weight gain, new onset or worsening edema, including pulmonary edema, hypotension or hemodynamic instability” | Regulatory label; not graded | Stemline Therapeutics, a Menarini Group company (DailyMed, US National Library of Medicine) 2024 |
| Tagraxofusp: capillary leak in 53% of 122 patients by the label's definition, median onset 4 days, four deaths “The median time to onset was 4 days (range - 1 to 46 days), and all but 5 patients experienced an event in Cycle 1.” | Regulatory label; not graded | Stemline Therapeutics, a Menarini Group company (DailyMed, US National Library of Medicine) 2024 |
| Tagraxofusp: the label's definition of capillary leak “hypoalbuminemia (including albumin value less than 3.0 g/dL), edema (including weight increase of 5 kg or more), hypotension (including systolic blood pressure less than 90 mmHg).” | Regulatory label; not graded | Stemline Therapeutics, a Menarini Group company (DailyMed, US National Library of Medicine) 2024 |
| Tagraxofusp: precautions as the consensus paper lists them in its discussion “monitoring and replacing of albumin, measurement of daily weights, albumin levels, vital signs (Body Temperature, Pulse Rate, Respiration Rate, Blood Pressure) during infusion days; hospitalization during cycle 1 for optimal administration; and appropriate use of diuretics when indicated, and employment of measures such as high-dose steroids for active treatment” | Consensus position paper, discussion text; not graded | HemaSphere (Pagano et al.; no funding statement printed; several panel members declare roles with Stemline or Menarini, which market tagraxofusp) 2023 |
| Dinutuximab: severe capillary leak in 31 patients (23%) in the registration trial “In Study 1, severe (Grade 3 to 5) capillary leak syndrome occurred in 31 (23%) patients in the Unituxin/RA group and in no patients treated with RA alone.” | Regulatory label; not graded | United Therapeutics (DailyMed, US National Library of Medicine) 2026 |
| Dinutuximab beta: stop permanently for recurrent or grade 4 capillary leak “recurrent or grade 4 capillary leak syndrome (requires ventilator support)” | Regulatory label; not graded | European Medicines Agency (marketing authorisation holder Recordati Netherlands B.V.) 2026 |
| Dinutuximab beta: timing of clinical signs “CLS usually develops within hours after initiation of treatment, while clinical symptoms (i.e. hypotension, tachycardia) are reported to occur after 2 to 12 hours.” | Regulatory label; not graded | European Medicines Agency (marketing authorisation holder Recordati Netherlands B.V.) 2026 |
| Aldesleukin: give in a hospital with intensive care “Administer Proleukin in a hospital setting with an intensive care facility.” | Regulatory label; not graded | Iovance Biotherapeutics (DailyMed, US National Library of Medicine) 2024 |
| No specific treatment exists for anticancer drug-induced capillary leak “There is no specific treatment of this drug side effect.” | Narrative review; not graded | Kidney International Reports (Izzedine et al.) 2022 |
| Evidence on fluid choice is lacking “There is a lack of evidence to guide the choice of fluid therapy.” | Narrative review; not graded | Kidney International Reports (Izzedine et al.) 2022 |
Shares Suspected febrile neutropenia (neutropenic sepsis): the first hour.
Shares Suspected febrile neutropenia (neutropenic sepsis): the first hour.